Class information for:
Level 1: HUHS1015//CHRONIC PROSTATIC INFLAMMATION//NAFTOPIDIL

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
20536 394 35.3 83%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
157 21931 BENIGN PROSTATIC HYPERPLASIA//PROSTATE CANCER//PROSTATE

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 HUHS1015 Author keyword 4 75% 1% 3
2 CHRONIC PROSTATIC INFLAMMATION Author keyword 3 60% 1% 3
3 NAFTOPIDIL Author keyword 2 16% 3% 10
4 ALPHA 1 ADRENOCEPTOR ANTAGONISTS Author keyword 1 31% 1% 4
5 ALPHA 1 ADRENERGIC DRUGS Author keyword 1 100% 1% 2
6 BXL628 Author keyword 1 100% 1% 2
7 CAS 57149 07 2 Author keyword 1 100% 1% 2
8 INDIANA BASIC UROL WORKING GRP Address 1 100% 1% 2
9 NAFTOPIDIL ANALOGUE Author keyword 1 100% 1% 2
10 ELOCALCITOL Author keyword 1 40% 1% 2

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 HUHS1015 4 75% 1% 3 Search HUHS1015 Search HUHS1015
2 CHRONIC PROSTATIC INFLAMMATION 3 60% 1% 3 Search CHRONIC+PROSTATIC+INFLAMMATION Search CHRONIC+PROSTATIC+INFLAMMATION
3 NAFTOPIDIL 2 16% 3% 10 Search NAFTOPIDIL Search NAFTOPIDIL
4 ALPHA 1 ADRENOCEPTOR ANTAGONISTS 1 31% 1% 4 Search ALPHA+1+ADRENOCEPTOR+ANTAGONISTS Search ALPHA+1+ADRENOCEPTOR+ANTAGONISTS
5 ALPHA 1 ADRENERGIC DRUGS 1 100% 1% 2 Search ALPHA+1+ADRENERGIC+DRUGS Search ALPHA+1+ADRENERGIC+DRUGS
6 BXL628 1 100% 1% 2 Search BXL628 Search BXL628
7 CAS 57149 07 2 1 100% 1% 2 Search CAS+57149+07+2 Search CAS+57149+07+2
8 NAFTOPIDIL ANALOGUE 1 100% 1% 2 Search NAFTOPIDIL+ANALOGUE Search NAFTOPIDIL+ANALOGUE
9 ELOCALCITOL 1 40% 1% 2 Search ELOCALCITOL Search ELOCALCITOL
10 ALPHA 1 ADRENERGIC INHIBITOR 1 50% 0% 1 Search ALPHA+1+ADRENERGIC+INHIBITOR Search ALPHA+1+ADRENERGIC+INHIBITOR

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 PARACRINE INDUCER 15 77% 3% 10
2 EPITHELIAL GROWTH FACTOR 7 67% 2% 6
3 ALPHA 1 ADRENOCEPTOR ANTAGONIST TERAZOSIN 3 60% 1% 3
4 HYPERPLASIA BPH 3 28% 2% 8
5 RECONSTITUTIONS 2 67% 1% 2
6 ALPHA 1 ADRENOCEPTOR ANTAGONISTS 2 16% 3% 10
7 ANTAGONIST DOXAZOSIN 1 100% 1% 2
8 SELECTIVE ALPHA1 ADRENOCEPTOR ANTAGONIST 1 100% 1% 2
9 CALCITRIOL ANALOG 1 33% 1% 3
10 DOXAZOSIN INDUCES APOPTOSIS 1 30% 1% 3

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Correlation between benign prostatic hyperplasia and inflammation 2013 23 49 65%
The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH) 2013 27 44 57%
The Controversial Relationship Between Benign Prostatic Hyperplasia and Prostate Cancer: The Role of Inflammation 2011 77 74 38%
Could inflammation be a key component in the progression of benign prostatic hyperplasia? 2006 65 20 75%
Oxidative Stress in Benign Prostatic Hyperplasia: A Systematic Review 2015 1 31 26%
Chronic inflammation in the pathogenesis of benign prostatic hyperplasia 2010 50 128 28%
Therapeutic Value of Quinazoline-based Compounds in Prostate Cancer 2013 12 60 30%
Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? 2007 157 71 31%
Serenoa Repens, Lycopene and Selenium Versus Tamsulosin for the Treatment of LUTS/BPH. An Italian Multicenter Double-Blinded Randomized Study Between Single or Combination Therapy (PROCOMB Trial) 2014 1 20 40%
The functional role of reactive stroma in benign prostatic hyperplasia 2011 28 130 19%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ.
in class
1 INDIANA BASIC UROL WORKING GRP 1 100% 0.5% 2
2 CORE IL ULTRASTRUCT ANAL 1 27% 0.8% 3
3 M ASCOLI CANC 1 50% 0.3% 1
4 MED HUMAN PATHOL 1 50% 0.3% 1
5 NUTR EPIDEMIOL PREVENT MED 1 50% 0.3% 1
6 PHARM FARMACOBIOL 1 50% 0.3% 1
7 UNITAT CIENT TECN SUPORT 1 50% 0.3% 1
8 WELLNESS TECHNOL RD GRP 1 50% 0.3% 1
9 WHITE SANDS 1 50% 0.3% 1
10 ZAKLAD RADIOBIOL DOSWIADCZALNEJ KLIN 1 50% 0.3% 1

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000254274 LOWER URINARY TRACT SYMPTOMS//BENIGN PROSTATIC HYPERPLASIA//LUTS
2 0.0000224938 D 004//PC SPES//SERENOA REPENS
3 0.0000216274 PROSTATITIS//CHRONIC PELVIC PAIN SYNDROME//CHRONIC PROSTATITIS
4 0.0000203386 PROSTATE DEVELOPMENT//BIOL SCI VET MED//PROSTATE STEM CELL
5 0.0000200648 UNIT IMMUNOMICROBIO ENVIRONM CARCINOGENESIS//ANTI INTERLEUKIN 6 ANTIBODY//AUTOCRINE AND PARACRINE LOOPS
6 0.0000133978 PEROPERATIVE BLEEDING//PRIMARY PROSTATE CULTURE//BLOOD VESSEL MORPHOLOGY
7 0.0000107988 INVERTED PAPILLOMA//PAPILLOMA INVERTED//REPROD PERINATAL MED
8 0.0000087525 PROSTATIC INTRAEPITHELIAL NEOPLASIA//ATYPICAL SMALL ACINAR PROLIFERATION//ALPHA METHYLACYL COA RACEMASE
9 0.0000075887 CYMBOPOGON CITRATUS//CYMBOPOGON CITRATUS STAPF//PECTIS BREVIPEDUNCULATA
10 0.0000069092 ALPHA1 ADRENOCEPTOR SUBTYPE//CHLOROETHYLCLONIDINE//ALPHA1B ADRENOCEPTOR